These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20525462)

  • 1. [Risk of anastomotic leakage in postoperative treatment with non-steroidal anti-inflammatory drugs].
    Klein M; Gögenur I; Rosenberg J
    Ugeskr Laeger; 2010 May; 172(22):1660-2. PubMed ID: 20525462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative non-steroidal anti-inflammatory drugs and colorectal anastomotic leakage. NSAIDs and anastomotic leakage.
    Klein M
    Dan Med J; 2012 Mar; 59(3):B4420. PubMed ID: 22381097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery.
    Holte K; Andersen J; Jakobsen DH; Kehlet H
    Br J Surg; 2009 Jun; 96(6):650-4. PubMed ID: 19434706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of postoperative diclofenac on anastomotic healing, skin wounds and subcutaneous collagen accumulation: a randomized, blinded, placebo-controlled, experimental study.
    Klein M; Krarup PM; Kongsbak MB; Agren MS; Gögenur I; Jorgensen LN; Rosenberg J
    Eur Surg Res; 2012; 48(2):73-8. PubMed ID: 22343935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of anastomotic leakage with diclofenac treatment after laparoscopic colorectal surgery.
    Klein M; Andersen LP; Harvald T; Rosenberg J; Gogenur I
    Dig Surg; 2009; 26(1):27-30. PubMed ID: 19153492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diclofenac on cyclooxygenase-2 levels and early breaking strength of experimental colonic anastomoses and skin incisions.
    Klein M; Krarup PM; Burcharth J; Ågren MS; Gögenur I; Jorgensen LN; Rosenberg J
    Eur Surg Res; 2011; 46(1):26-31. PubMed ID: 21135559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of anastomotic leakage with non-steroidal anti-inflammatory drugs in colorectal surgery.
    Gorissen KJ; Benning D; Berghmans T; Snoeijs MG; Sosef MN; Hulsewe KW; Luyer MD
    Br J Surg; 2012 May; 99(5):721-7. PubMed ID: 22318712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data.
    Klein M; Gögenur I; Rosenberg J
    BMJ; 2012 Sep; 345():e6166. PubMed ID: 23015299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.
    Feczko J
    BMJ; 2005 Dec; 331(7530):1473-4. PubMed ID: 16356991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.